Kerx: Hi Dew,
As I was saying from before, the trial is only 16.7% powered. When the trial 3 reaches 1000 pts, it will be 90% powered and
we can be more defenitive of the data.
From the power pt presentation, efficacy is clear. placebo:11% 200mg dose: 33%. They were 20 trials done in the process which proved the drug works. Also there were no sig side effects and no dose toxicities. I feel this drug might work to a certain extent and has a good chance for approval because the FDA's SPA endpoint is not very high. This will be a first mover and later others like speedel might better it.
But the cancer drug krx 401 is the one I am really interested in...It is a new class and the moa is very novel. I will keep this on the radar and once I know more abt 401 and 101, I will let you know.
Regards,
Dr.Praveen
Market Data 
Markets 
AI
